A 2026 ADNI study reported 85.23% accuracy for ANA-GNN, a graph neural network that combined structural MRI regional features with clinical variables to classify cognitively normal controls, mild cognitive impairment, and Alzheimer’s disease.1 The result is useful, but the clinical-feature ablation dropped accuracy to 68.35%, so the model should be read as multimodal decision-support research, …
A 2026 single-cell and spatial-transcriptomics study of 21,156 brain immune cells found that late amyloid disease shifted interferon-driven neuroinflammation from microglia toward plaque-associated CD8 T cells, with T-cell frequency strongly tracking total amyloid deposits (Spearman rho = 0.844, p < 0.0001).1 The result does not turn Alzheimer’s disease into an autoimmune disease, but it makes …
A 2026 iScience study found that 45 days of clomipramine improved spatial, working, and reference memory in female APP/PS1 Alzheimer’s-model mice, apparently by blocking the E3 ubiquitin ligase Itch rather than by clearing amyloid plaques.1 Research Highlights 45-day clomipramine signal: 6-month female APP/PS1 mice received 25 mg/kg clomipramine every other day for 45 days, then …
Statins do not look like a dementia-prevention drug, but they do not look like a dementia hazard either. In 322,358 Kaiser Permanente Northern California patients followed for an average of 11.8 years, dementia diagnoses rose right after statins were started, then flattened: after the first year, the hazard ratio for Alzheimer’s disease and related dementias …
A 2026 Molecular Psychiatry study found that RVI-AD, a structural-MRI score measuring how closely a person’s brain anatomy matches an Alzheimer’s disease pattern, predicted mild-cognitive-impairment conversion to dementia most strongly over the next 3 years: OR 2.16, 95% CI 1.81-2.57, p < 2e-16, AUC 0.70.1 Research Highlights Short-term conversion signal: in 965 ADNI participants with …
A 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both present: X-34 plaque area differed across IgG1, lecanemab, and Fc-silenced LALA-PG groups (P = 0.0003), 82E1 plaque area differed across groups (P < 0.0001), and microglia-deficient mice showed …
A 2026 total-body tau-PET study of 28 people with Alzheimer’s disease and 23 biomarker-negative controls found stronger brain-organ network connectivity in Alzheimer’s disease than in biomarker-negative controls: 35 altered connections, including 21 brain-body edges, plus AD-only links between brain-organ coupling, cortical tau burden, MRI-derived glymphatic markers, and cognition.1 The result is best read as a …